Hot Investor Mandate: China-Based Corporate Venture Firm Invests in Early-Stage Life Science Technologies with China Angle and Strong Market Potential

2 Jan

A firm with offices in China is managing two funds in RMB with a total of over 300M RMB, and is planning to raise a USD fund in the near future.

The firm is currently focusing on early-stage (from angel to series A) investments, each investment ranging from 5MM RMB (~0.7MM) to 20MM RMB (~3MM).

With the support of a synergistic incubator business and its accelerating program, as well as a dynamic innovation ecosystem built upon these business arms, the firm has a broad reach of disruptive technologies and is progressively investing in the field of life science to support the business strategy and organic growth of their parent company.

The firm is mainly looking at fields of next generation of molecule diagnostics, microfluidics, synthetic biology, omics technology, bioinformatics, genetic testing, gene therapy and immunotherapy, microbiome, etc. The firm is open to investing in the field of life science and precision medicine, focusing on the frontier research and technologies in DNA, RNA, protein, cell, tissue and other integrative omics. Therapeutics, especially gene therapy, oncology therapy, and eye disease therapy; diagnostics sector, especially in gene detection, molecular diagnostics, CNS and IVD; also some medical devices. However, the firm has less interest in technologies that are already in the field of very fierce competition, with big players already in.

The firm prefers companies with a China angle, especially companies who are willing to register an entity in China. They mostly are interested in companies with novel and original technologies and a clear direction of clinical applications.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: CVC Arm of Pharmaceutical Company Seeks Digital Health Technologies and Platforms Addressing Chronic Diseases and Other High Unmet Medical Need

2 Jan

A  corporate venture capital arm of a global pharmaceutical with headquarters in Western Europe can invest up to $5m to a round. They will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. They are open to working with companies globally.

Within digital health, the firm is seeking companies that are in the prevention and adherence space as well as digital medical devices and big data analytics platforms that address chronic diseases (Diabetes, Obesity and Cardiovascular), respiratory diseases, oncology, consumer and mental health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with management teams with a track record in the space and a strong business plan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Family Office Associated Investment Firm Seeks Early-Stage Medical Device and Diagnostic Technologies, as well as Therapeutics

2 Jan

An investment firm located in the USA and associate with a family office registered in the Cayman Islands is managing a $100MM fund, the firm invests in angel and seed stage, and its typical allocation size is between $200,000 to $750,000. The firm invests in companies based in the United States, especially in the Silicon Valley area, and normally invests four to five companies every year.

The firm is interested in diagnostics and medical devices in general, especially cancer diagnostics. Regarding therapeutics, it is open to the data platforms for therapeutics and orphan diseases.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI San Francisco 2020 Innovation Challenge Finalists Selected

19 Dec

By Claire Jeong, Director of Research, Asia BD, LSN

claire

We’re excited to announce the RESI San Francisco Innovation Challenge finalist companies (just in time for the holidays!). With RESI San Francisco being our most popular event, over 150 innovative companies across therapeutics, devices, diagnostics, and digital health applied to participate.

For those of you who are not familiar with the Innovation Challenge, this is a competition we organize at every RESI conference. Finalists will bring a posterboard showcasing their company and technology, which will be presented at a dedicated exhibition hall for the entire day. All attendees will be provided with “RESI Cash”, which they can use to “invest” in their favorite, most innovative companies. The Top 3 winners with the most RESI Cash will be announced during our cocktail reception.

Whether you will be attending RESI San Francisco or not, we highly recommend that you check out these companies through their clickable logos and see what they have to offer. Best of luck to the participating companies, and we look forward to seeing all of the incredible technologies next month on January 14th!

Therapeutics

Medical Devices

 

Diagnostics

Digital Health

Announcing the Featured Company Pitch Sessions – Watch These Startups Present at RESI San Francisco 2020

19 Dec

By Karen Deyo, Senior Investor Research Analyst, LSN

For RESI San Francisco, LSN introduced the new Featured Company Pitch Session, an opportunity for companies to register to pitch at RESI San Francisco. There was an overwhelming response, with over 150 applications for the limited spots available. The morning sessions are focused on companies in therapeutics, medical devices and advanced platforms and tools, plus a session sponsored by Dayli Partners featuring their most innovative portfolio companies. In the afternoon, Global Family Office Bioforum will lead three focused sessions on Alzheimer’s Diagnosis & Treatments, Cancer Diagnostics, and Women CEOs.  All these sessions will take place in RESI’s theatre on the 2nd floor of Marines’ Memorial Club & Hotel.  Make sure to block off time on your schedule at RESI San Francisco to see these companies pitch!

8:00AM – 9:00AM
BIOTECH ENTREPRENEUR PITCH SESSION
9:00AM -10:00AM
MEDTECH ENTREPRENEUR PITCH SESSION
10:00AM – 11:00AM
ADVANCED PLATFORMS & TOOLS PITCH SESSION
11:00AM – 12:00AM
KOREA ENTREPRENEUR PITCH SESSION
SPONSORED BY 
1:00PM – 2:00PM
ALZHEIMER’S DIAGNOSIS & TREATMENT PITCH SESSION
SPONSORED BY 
2:00PM – 3:00PM
WOMEN CEOs PITCH SESSION
SPONSORED BY 

 
3:00PM – 4:00PM
CANCER DIAGNOSTICS PITCH SESSION
SPONSORED BY 

How Do You Measure Your Partnering Meeting Success?

19 Dec

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

It’s challenging to raise an early stage financing round.  You need to build strong marketing collateral, and only then launch an outbound financing campaign. And then, you face the challenge of how to measure the effectiveness of the myriad partnering events you might attend during your campaign.  How does a scientist-entrepreneur gauge how a meeting went and what are the metrics they should use?  When running a fundraising campaign executives need to be vigilant in ranking which meetings were successful and may lead to further dialogue.  One learning milestone for all fundraising CEOs is being diligent about which players stay on the list and which ones are removed because of lack of interest or lack of fit.

LSN’s RESI Conference Series offers attendees a partnering system with a built in “matching algorithm” that will parse all the investors and recommend with which investors the companies should try and connect. The algorithm is based on the investor’s criteria in terms of product, stage of development, and other key parameters.  When a company gives a pitch at RESI Conference to an investor audience or meets an investor in a one-on-one meeting, they are pitching to potential partners that are a fit for them.  Typically at other partnering venues, up to half of the thirty minute meeting is trying to determine “who is selling who” and what the person on the other side of the table is seeking.  RESI Partnering has eliminated that downside.

Many conferences have partnering as a “me too” segment, as opposed to RESI, which is a dedicated partnering conference; all the partners at RESI have been screened for fit and vetted to ensure they are active investors with current investment mandates in order to comply with RESI’s investor pass program.  Another distinct feature when you attend a RESI conference is that investors can also be identified by the red ribbons on their badges!

Here are some important metrics to consider:

–Fit. This is the most important metric in meetings.  Did a company meet a potential partner that was a fit for their stage of development and product?

–Did the investor want to have a follow-up meeting?

-Did they express interest in signing an NDA?

-Did they refer you to other peers, colleagues or investors?

-Did they take the time to engage you at other times during the networking activities and receptions?

These metrics are what determines  “success” at a partnering event.  By using the information gathered by LSN’s Investor Research team fundraising executive and investors are more efficient and as a result have much more compelling meetings. With the possibility of booking up to 16 meetings at each RESI event, a scientist-entrepreneur attending RESI’s regular US and international events can connect with investors that are a good fit on a global level.  As fundraising is a numbers game, good meetings that are a fit  are the key to your company’s success.

Hot Investor Mandate: Venture Fund Invests US-Wide in 510k Devices

19 Dec

A venture firm based in California makes early stage investments ranging from $100k – $3M, occasionally making larger investments outside of this range.  The firm is flexible in terms of structure with both equity and convertible notes being used. The group will fund, incubate and help develop new technologies at the earliest stages (ideas with no IP) as well as invest in established venture stage companies. The firm will both lead rounds as well as invest with a syndicate. The firm is focused on companies and technologies based in the USA or having their primary business in the USA.

The firm is primarily focused on the medtech and device space, and will evaluate diagnostic technologies that have a device component (tests/IVDS, etc. are not considered). The group is fairly opportunistic, however has specific interests in orthopedics, dermatology, neurovascular, endovascular, women’s health, ophthalmology and general surgical devices and products. The firm is only interested in technologies with a 510(k) regulatory pathway. The group will invest in devices/products in development or at the clinical stage.

The firm has no stricture company or management requirements and is open to working with all entrepreneurs. The company may seek a board seat long with investment, but it is not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →